





# **Hepatitis Scorecard**

Member state

Algeria

Angola

Benin

Botswana

Burundi

Burkina Faso

Cabo Verde

Cameroon

Chad

Congo

Eritrea

Eswatini

Ethiopia

The Gambia

Guinea Bissau

Gabon

Ghana

Guinea

Kenya

Lesotho

Liberia

Malawi

Mali

Madagascar

Mauritania

Mauritius

Namibia

Niger

Nigeria

Rwanda

Senegal

Seychelles

Sierria Leone

South Africa\*

South Sudan

Tanzania

Togo

Uganda

Zambia

Zimbabwe

São Tomé and Principe

Mozambique

Comoros

Cote-d'Ivore

Equatorial Guinea

Central African Republic

Democratic Republic of the Congo

## **Country Burden** Hepatitis B Hepatitis B in Population Children <5 yrs % HBsAg Prevalence\* 2015 Estimated number of chronic carriers('000s) Estimated number of chronic carriers('000s) % HBsAg Prevalence

1,8

9.4

1,3

64

4,4

4.9

4.3

32

1,9

2,1

9.1

5,8

8.6

13

2,2

4,5

14,9

69

8.5

1,9

2.2

45

3.5

0,4

18,6

3.5

22,2

4.1

695

2351

1191

31

1820

711

27

1034

499

684

34

439

1377

2435

79

96

26

5647

157

115

2365

1639

94

1000

96

671

1977

1188

1503

416

23

2025

54

2310

9966

524

6

1237

0

1203

1924

2734

2155

617

2456

657

1570

0,2

4,9

0,2

4,3

2,6

0.7

1,9

3.1

2,0

4,1

3,0

1.4

8,7

0,7

0,9

2,6

4.2

1,2

3.6

7,5

2,6

0,9

1,6

4,4

3.0

49

4,3

3,7

0.7

2,6

1,7

1.4

3,5

0,2

8,2

1.7

21,1

1,7

3,4

3,2

1.8

10

229

95

135

53

0

71

47

81

2

31

111

198

11

1

381

10

146

153

6

62

5

54

164

89

160

26

0

177

2

249

812

30

0

91

0

82

93

413

159

39

230

52

Hepatitis C

Anti-HCV prevalence (\*\* viraemic prevalence)

0,2

0.4

4.8

0,1

1.3\*\*

10\*\*

0,1

0.7\*\*

0.3\*\*

11\*\*

1,4

1,8

1.7

18

NR

0,8

0,0

0.6\*\*

7.0\*\*

0.8\*\* 14\*\*

1,0

0,7

0.2\*\*

0.7

NR

0.2\*\*

1.1

31

0,0

0,3

0,5 0.1

1,5

2,1

1.6

0.3

0,2

NR

1,2

0.7\*\*

4,3

0,0

1,1

1.0

1,0

	Indicators				
#1 Hepatitis Policy	#2 Hepatitis Pr	#3 revention	#4 Hepatitis s Treat	#5 creening & ment	#6
National Strategic plan for Viral Hepatitis	HBV Birth dose implemented	HEP B3 national coverage >90%	2020 HBV/HCV testing target on tract	National Hepatitis treatment programmes	World Hepatitis Day 2018

Key to the
6 indicators

National strategic plans for viral hepatitis. Countries with high burden of disease require disease specific plans developed at the most focused levels for specific projects with time bound interventions

### #2 Hepatitis B birth dose implemented

Coverage estimates are derived from WHO UNICEF Joint Reporting (updated July 2016)

Monovalent hepatitis B birth dose within 24 hours is required for prevention of mother-to-child and early perinatal transmission of hepatitis B. \*\*Mauritius implementing selective hepatitis B birth dose administration in positive pregnant women.

#3 National coverage of the third dose of pentavalent vaccine
All African countries have incorporated hepatitis B vaccine into their
Expanded Programme for Immunization schedules. Indicator 3 reflects the national coverage of the third dose of the three-dose pentavalent vaccine. (ref. United Nations Hepatitis b coverage for 2016 and 2017). The 2020 target of >90% (Global Health Sector Strategy on Viral Hepatitis).

#4 20% of people living with hepatitis B and C know their status This is the 2020 testing target, which can be reached with the implementation of public health programmes.

#5 Establishment of national treatment programmes
Although most countries have hepatitis B and C care at tertiary and specialist centres, hepatitis elimination requires a public health and decentralization approach. Eight countries are demonstrating significant initiatives in supporting demonstration projects or have access programmes for hepatitis B or C supported by partners Free screening and/or provision of antiviral therapy (highly subsidized or free) has been provided and taken to scale only in

### #6 World Hepatitis Day

Leadership of the health ministry in the commemoration of World Hepatitis Day 2018. Important for advocacy and government action

High intermediate/high >5% prevalence

Low intermediate prevalence 2-4%

Low Prevalence < 2%

Not on track

On track

Complete

Not available









